Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-positive advanced breast cancer Ib/II single-arm study
CTR20213419Phase 2Completed
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in breast cancer, sponsored by Zhejiang Medicine Co., Ltd.. Started Mar 2022; status: completed.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20213419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213419.